Ascidian Therapeutics

We are a team in relentless pursuit of game changing solutions in human health. We believe that the development of small molecule drugs that modulate RNA will dramatically change patient outcomes for diseases where treatment options for patients are currently limited. Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Our team's work is founded upon leading research emerging from Scripps Research.

We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141. Our mission is to create immunotherapies and vaccines that deliver extraordinary benefits to patients around the world. Ascendo Biotechnology is a fast-growing biotechnology company based in Taiwan that is pioneering novel approaches to developing cancer immunotherapies and functional cures for chronic viral infections. Our therapeutic strategies focus on the interplay between the natural innate and adaptive immune pathways to reinvigorate the immunity of the tumor microenvironment for a comprehensive anti-tumor response. Our lead oncology product, ASD141, is an innate immune checkpoint inhibitor (ICI) that commands a controlled, active innate immune response to solid tumors. In addition to ICIs, we are building a diverse pipeline which includes NanoCherub®, our nanocomplex platform technology of which several our early-stage injectable, oral therapeutic and prophylactic vaccines are based. Ascendo is a spin-out from BRIM Biotechnology and was fully incorporated in 2019 having raised USD 12 million in seed funding and financing in 2020. Chien returned to Taiwan and joined the National Health Research Institutes as the Associate Director of the Division of Biotechnology and Pharmaceutical Research.

Enzerna Biosciences, Inc is a pre-clinical stage company that is leveraging its proprietary RNA editing technology to develop long-term curative gene therapies for rare genetic disorders. Enzerna has secured an exclusive license for ASRE technology (US Patent No. Enzerna Biosciences INC 5151 McCrimmon Pkwy Suite 240 Morrisville, NC 27560. Our solution is to destroy the toxic RNA molecule that is the root cause of nucleotide expansion disorders using Artificial Site-Specific RNA Endonucleases (ASREs). A look at the science behind Enzerna’s unique technology and how it effects disease. This type of muscular dystrophy is a genetic disorder that affects muscle function.

Pioneering RNA editing to deliver the future of medicine.

We’re a clinical stage biotech co-founded by the Nobel scientist who discovered RNA interference. Our proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies.

We are a Biotech-startup focused on developing novel genetic therapies. Our goal is to develop novel therapies that target only cells causing a disease, with minimal patient burden. We are looking to develop revolutionary new treatments with partner companies using RNA Switches. We believe our ingenuity and curiosity can lead us to the future. Fumihiro Sugawa will serve as the new President and CEO.